Celldex Therapeutics Stock Price, News & Analysis (NASDAQ:CLDX)

$2.35 +0.04 (+1.73 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$2.35
Today's Range$2.32 - $2.40
52-Week Range$2.20 - $3.94
Volume2.17 million shs
Average Volume1.24 million shs
Market Capitalization$319.57 million
P/E Ratio-2.33
Dividend YieldN/A
Beta2.57

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CLDX
CUSIP15117B10
Phone+1-908-2007500

Debt

Debt-to-Equity RatioN/A
Current Ratio5.91%
Quick Ratio5.91%

Price-To-Earnings

Trailing P/E Ratio-2.32673267326733
Forward P/E Ratio-2.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.79 million
Price / Sales47.07
Cash FlowN/A
Price / CashN/A
Book Value$2.17 per share
Price / Book1.08

Profitability

Trailing EPS($1.01)
Net Income$-128,530,000.00
Net Margins-1,088.58%
Return on Equity-46.94%
Return on Assets-32.11%

Miscellaneous

Employees210
Outstanding Shares135,990,000

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.07. The biopharmaceutical company earned $3.90 million during the quarter, compared to analysts' expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The business's revenue for the quarter was up 77.3% on a year-over-year basis. During the same period last year, the firm earned ($0.29) EPS. View Celldex Therapeutics' Earnings History.

When will Celldex Therapeutics make its next earnings announcement?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Celldex Therapeutics.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2018?

6 Wall Street analysts have issued 12-month price objectives for Celldex Therapeutics' shares. Their predictions range from $3.50 to $10.00. On average, they expect Celldex Therapeutics' share price to reach $8.13 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
  • 2. Cowen Inc analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board (Age 69)
  • Anthony S. Marucci, President, Chief Executive Officer, Director (Age 55)
  • Sam Martin, Chief Financial Officer, Senior Vice President (Age 46)
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer (Age 58)
  • Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration (Age 42)
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer (Age 45)
  • Margo Heath-Chiozzi, Senior Vice President - Regulatory Affairs (Age 60)
  • Theresa M. LaVallee Ph.D., , Senior Vice President - Regulatory and Precision Medicine (Age 50)
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer (Age 61)
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer` (Age 53)

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.30%), Millennium Management LLC (1.65%), TSP Capital Management Group LLC (0.94%), Geode Capital Management LLC (0.81%), Ascend Capital LLC (0.64%) and Deutsche Bank AG (0.52%). View Institutional Ownership Trends for Celldex Therapeutics.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Ascend Capital LLC, Artal Group S.A., Deutsche Bank AG, AXA, Goldman Sachs Group Inc., Vident Investment Advisory LLC, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. View Insider Buying and Selling for Celldex Therapeutics.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., TIAA CREF Investment Management LLC, Geode Capital Management LLC, TSP Capital Management Group LLC, Virtus Fund Advisers LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.35.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $319.57 million and generates $6.79 million in revenue each year. The biopharmaceutical company earns $-128,530,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Celldex Therapeutics employs 210 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 Frontage Rd Ste 220, HAMPTON, NJ 08827-4034, United States. The biopharmaceutical company can be reached via phone at +1-908-2007500 or via email at [email protected]


MarketBeat Community Rating for Celldex Therapeutics (CLDX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celldex Therapeutics (NASDAQ:CLDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.802.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.13$8.13$7.50$8.08
Price Target Upside: 237.14% upside180.17% upside172.73% upside215.76% upside

Celldex Therapeutics (NASDAQ:CLDX) Consensus Price Target History

Price Target History for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
12/6/2017WBB SecuritiesReiterated RatingBuy$10.00LowView Rating Details
9/26/2017Cantor FitzgeraldReiterated RatingBuy$9.00LowView Rating Details
6/29/2017AegisReiterated RatingBuyMediumView Rating Details
6/6/2017CowenReiterated RatingBuyHighView Rating Details
5/11/2017Jefferies GroupReiterated RatingHold$4.00 -> $3.50HighView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016OppenheimerDowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Celldex Therapeutics (NASDAQ:CLDX) Earnings History and Estimates Chart

Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ CLDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.25)N/AView Earnings Details
11/7/2017Q3 2017($0.27)($0.20)$1.30 million$3.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.23)$1.21 million$3.83 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.26)($0.27)ViewN/AView Earnings Details
8/3/2011Q2 2011($0.28)($0.27)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.30)($0.30)ViewN/AView Earnings Details
3/3/2011Q4 2010$0.21($0.24)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.33)($0.29)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.26)($0.30)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.26)($0.16)ViewN/AView Earnings Details
3/4/2010Q4 2009($0.29)($0.27)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.56)($0.45)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.47)($0.55)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.46)($0.49)ViewN/AView Earnings Details
2/27/2009Q4 2008($0.54)($0.47)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.41)($0.50)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.56)($0.67)ViewN/AView Earnings Details
5/19/2008Q1 2008($0.67)($0.73)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.84)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celldex Therapeutics (NASDAQ:CLDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.9 EPS

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celldex Therapeutics (NASDAQ CLDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 55.65%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ CLDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.0018,868View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.0035,109View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.0053,500View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.0048,500View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.0043,500View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.5014,109View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.0025,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celldex Therapeutics (NASDAQ CLDX) News Headlines

Source:
DateHeadline
$1.91 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter$1.91 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - February 15 at 3:36 AM
Celldex Therapeutics, Inc. (CLDX) Expected to Announce Earnings of -$0.23 Per ShareCelldex Therapeutics, Inc. (CLDX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 13 at 5:20 PM
Celldex Therapeutics (CLDX) Given a $10.00 Price Target by HC Wainwright AnalystsCelldex Therapeutics (CLDX) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 10 at 4:44 PM
Celldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of "Hold" from BrokeragesCelldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 3:46 PM
Is Celldex Therapeutics, Inc. (CLDX) a Buy? - Motley FoolIs Celldex Therapeutics, Inc. (CLDX) a Buy? - Motley Fool
www.fool.com - February 2 at 4:05 PM
Is Celldex Therapeutics, Inc. (CLDX) a Buy?Is Celldex Therapeutics, Inc. (CLDX) a Buy?
finance.yahoo.com - January 31 at 10:03 AM
Celldex Therapeutics, Inc. (CLDX) Expected to Post Quarterly Sales of $1.91 MillionCelldex Therapeutics, Inc. (CLDX) Expected to Post Quarterly Sales of $1.91 Million
www.americanbankingnews.com - January 29 at 2:58 AM
What to Expect From Celldex Therapeutics, Inc. in 2018What to Expect From Celldex Therapeutics, Inc. in 2018
finance.yahoo.com - January 27 at 10:00 AM
Financial Comparison: Abeona Therapeutics (ABEO) vs. Celldex Therapeutics (CLDX)Financial Comparison: Abeona Therapeutics (ABEO) vs. Celldex Therapeutics (CLDX)
www.americanbankingnews.com - January 20 at 1:10 AM
Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by BrokeragesCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 16 at 3:44 PM
Will 2018 Be Celldex Therapeutics, Inc.s Best Year Yet?Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet?
www.fool.com - January 16 at 9:39 AM
Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet?Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet?
finance.yahoo.com - January 16 at 9:39 AM
Celldex Therapeutics (CLDX) Stock Rating Lowered by BidaskClubCelldex Therapeutics (CLDX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 15 at 12:44 AM
AbbVie's Upadacitinib Gains Breakthrough Therapy DesignationAbbVie's Upadacitinib Gains Breakthrough Therapy Designation
finance.yahoo.com - January 9 at 5:19 PM
Celldex Therapeutics (CLDX) Raised to Sell at BidaskClubCelldex Therapeutics (CLDX) Raised to Sell at BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
3 Biotech Stocks to Buy in January3 Biotech Stocks to Buy in January
finance.yahoo.com - January 3 at 8:48 AM
4 Reasons To Consider Adding Celldex To Your Portfolio4 Reasons To Consider Adding Celldex To Your Portfolio
feeds.benzinga.com - January 2 at 1:36 PM
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio
www.zacks.com - January 2 at 9:33 AM
ETFs with exposure to Celldex Therapeutics, Inc. : December 19, 2017ETFs with exposure to Celldex Therapeutics, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:14 PM
Celldex Therapeutics Inc (NASDAQ:CLDX)’s Earnings Grew 23%, Is It Enough?Celldex Therapeutics Inc (NASDAQ:CLDX)’s Earnings Grew 23%, Is It Enough?
finance.yahoo.com - December 14 at 9:44 AM
Why Celldex Therapeutics Stock Reversed Course in November - Motley FoolWhy Celldex Therapeutics Stock Reversed Course in November - Motley Fool
www.fool.com - December 10 at 5:25 PM
Why Celldex Therapeutics Stock Reversed Course in NovemberWhy Celldex Therapeutics Stock Reversed Course in November
www.fool.com - December 10 at 9:40 AM
 Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million
www.americanbankingnews.com - December 9 at 10:56 AM
ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:08 PM
Zacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.20 Per ShareZacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 7 at 1:14 PM
Celldex Therapeutics (CLDX) Rating Reiterated by WBB SecuritiesCelldex Therapeutics (CLDX) Rating Reiterated by WBB Securities
www.americanbankingnews.com - December 6 at 11:58 AM
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 ... - NasdaqCelldex Begins Phase I Trial on Cancer Candidate CDX-1140 ... - Nasdaq
www.nasdaq.com - December 2 at 9:44 AM
Celldex (CLDX) Commences Phase 1 Study of New Product Candidate CDX-1140 in Solid TumorsCelldex (CLDX) Commences Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
www.streetinsider.com - December 1 at 4:56 PM
Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid TumorsCelldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
finance.yahoo.com - November 30 at 10:04 AM
Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
www.fool.com - November 30 at 9:31 AM
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
finance.yahoo.com - November 29 at 9:43 AM
Celldex Therapeutics, Inc. (CLDX) Given Average Rating of "Hold" by AnalystsCelldex Therapeutics, Inc. (CLDX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 27 at 4:52 PM
Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and ... - PR Newswire (press release)Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and ... - PR Newswire (press release)
www.prnewswire.com - November 22 at 5:58 PM
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate - NasdaqCelldex (CLDX) Initiates Phase II Study on Cancer Candidate - Nasdaq
www.nasdaq.com - November 22 at 3:28 AM
Zacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 MillionZacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million
www.americanbankingnews.com - November 21 at 6:26 AM
ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:21 PM
Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per ShareCelldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 19 at 5:08 PM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 8:38 AM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell CarcinomaCelldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
finance.yahoo.com - November 18 at 8:38 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - NasdaqCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - November 10 at 9:53 AM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - November 9 at 8:30 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares UpCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
finance.yahoo.com - November 8 at 9:14 PM
ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 9:14 PM
Celldex reports 3Q lossCelldex reports 3Q loss
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a NumberCelldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
finance.yahoo.com - November 7 at 8:16 PM
How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc. (CLDX) Announces  Earnings ResultsCelldex Therapeutics, Inc. (CLDX) Announces Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Why Celldex Therapeutics Jumped Higher TodayWhy Celldex Therapeutics Jumped Higher Today
www.fool.com - November 7 at 2:41 PM

SEC Filings

Celldex Therapeutics (NASDAQ:CLDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celldex Therapeutics (NASDAQ:CLDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celldex Therapeutics (NASDAQ CLDX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.